Rituximab in lupus and beyond: the state of the art.
Hughes
G
G
The London Lupus Centre, London Bridge Hospital, London, UK. londonlupuscentre@hcahealthcare.co.uk
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D016736:Antiphospholipid Syndrome / Q000188:drug therapy; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001402:B-Lymphocytes / Q000473:pathology; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000473:pathology; D008212:Lymphocyte Depletion; D000069283:Rituximab; D014657:Vasculitis / Q000188:drug therapy
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D000069283:Rituximab